Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma

被引:0
作者
Fen Ma
Shuoer Wang
Lun Xu
Wending Huang
Guohai Shi
Zhengwang Sun
Weiluo Cai
Zhiqiang Wu
Yiming Huang
Juan Meng
Yining Sun
Meng Fang
Mo Cheng
Yingzheng Ji
Tu Hu
Yunkui Zhang
Bingxin Gu
Jiwei Zhang
Shaoli Song
Yidi Sun
Wangjun Yan
机构
[1] Shanghai University of Traditional Chinese Medicine,Shanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica
[2] Chinese Academy of Sciences,Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology
[3] Fudan University Shanghai Cancer Center,Department of Musculoskeletal Surgery
[4] Fudan University Shanghai Cancer Center,Department of Nuclear Medicine
[5] Fudan University,Department of Oncology, Shanghai Medical College
[6] Fudan University Shanghai Cancer Center,Department of Urology
[7] Second Military Medical University,Department of Orthopedic, Naval Medical Center of PLA
[8] Fudan University Shanghai Cancer Center,Department of Anesthesiology
来源
Communications Biology | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma. To explore the potential therapeutic targets for bone metastatic renal cell carcinoma, we profile single cell transcriptomes of 6 primary renal cell carcinoma and 9 bone metastatic renal cell carcinoma. We also include scRNA-seq data of early-stage renal cell carcinoma, late-stage renal cell carcinoma, normal kidneys and healthy bone marrow samples in the study to better understand the bone metastasis niche. The molecular properties and dynamic changes of major cell lineages in bone metastatic environment of renal cell carcinoma are characterized. Bone metastatic renal cell carcinoma is associated with multifaceted immune deficiency together with cancer-associated fibroblasts, specifically appearance of macrophages exhibiting malignant and pro-angiogenic features. We also reveal the dominance of immune inhibitory T cells in the bone metastatic renal cell carcinoma which can be partially restored by the treatment. Trajectory analysis showes that myeloid-derived suppressor cells are progenitors of macrophages in the bone metastatic renal cell carcinoma while monocytes are their progenitors in primary tumors and healthy bone marrows. Additionally, the infiltration of immune inhibitory CD47+ T cells is observed in bone metastatic tumors, which may be a result of reduced phagocytosis by SIRPA-expressing macrophages in the bone microenvironment. Together, our results provide a systematic view of various cell types in bone metastatic renal cell carcinoma and suggest avenues for therapeutic solutions.
引用
收藏
相关论文
共 118 条
  • [1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J. Clin. 68 394-424
  • [2] Siegel RL(2021)Cancer Statistics, 2021 Cancer J. Clin. 71 7-33
  • [3] Miller KD(2004)Renal cell carcinoma: etiology, incidence and epidemiology Curr. Opin. Urol. 14 229-233
  • [4] Fuchs HE(2021)Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response Proc. Natl Acad. Sci. USA 118 e2103240118-30
  • [5] Jemal A(2018)Cancer statistics, 2018 Cancer J. Clin. 68 7-584
  • [6] Murai M(2014)Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy Eur. Urol. 65 577-166
  • [7] Oya M(2011)Skeletal complications and survival in renal cancer patients with bone metastases Bone 48 160-6249s
  • [8] Zhang Y(2006)Clinical features of metastatic bone disease and risk of skeletal morbidity Clin. Cancer Res. 12 6243s-382
  • [9] Siegel RL(2001)The skeletal metastatic complications of renal cell carcinoma Int. J. Oncol. 19 379-892
  • [10] Miller KD(2015)Survival and complications of skeletal reconstructions after surgical treatment of bony metastatic renal cell carcinoma Eur. J. Surgical Oncol. 41 886-509